1. Introduction {#sec1}
===============

According to the WHO, approximately 1 million people commit suicide each year. Therefore, suicide is considered a major public health problem. The causes of suicidal behaviour and suicide attempts are complex in that both genetic and environmental factors can play a role. Exposure to an acute or chronic stress accompanied by psychiatric conditions, including substance abuse, depressed mood, anxiety, and also psychotic features, can lead to suicide attempts.

Family twin and adoption studies have noted the heritability of these features, suggesting that there is a specific biological influence on suicidal behaviour. Genes containing different variants, interindividual differences in psychology, and related stress resilience may cause a vulnerability to suicidal behaviour \[[@B32]\], as well as age, sex and the history of the trauma. A majority of the genetic studies have involved serotonin-related genes because levels of serotonin and its metabolites are thought to play a role in suicidal behaviour. Meta-analyses have confirmed an association between suicidal behaviour and 5HTT, (serotonin transporter), tryptophan hydroxylase (TPH1), and brain-derived neurotropic factor (BDNF) expression, as well as the expression of tyrosine kinase receptor type 2 (NTRK2) \[[@B21], [@B25]\].

The biological response to stress involves the hypothalamic-pituitary-adrenal axis (HPA), and prolonged stress may change its function. These changes can be marked by altered HPA activity (high or low cortisol levels) or reactivity (reduced or increased feedback regulation). These HPA disturbances are also thought to be partially predictive of suicidal behaviour \[[@B6]--[@B26]\] and are regarded as an endophenotype of suicidal behaviour \[[@B18]\]. In particular, AVP receptor upregulation may be critical for sustaining corticotropic responsiveness during chronic stress or depression \[[@B28]\]. Jokinen et al. suggested that dexamethasone suppression test (DST) nonsuppression may be a biological suicide predictor in depressed male suicide attempters \[[@B11], [@B13]\]. Those patients may be genetically predisposed to react with high levels of HPA activity in response to a low stress and may experience a chronic state of HPA activation \[[@B12], [@B14]\]. This reaction occurs most likely via altered *CRHR1* (the gene controlling activation of HPA axis) expression and functionality. Recently, Merali and colleagues found that *CRHR1* mRNA expression was changed in the frontal cortices of suicide victims \[[@B22]\]. Hyperactivity of the HPA axis predicts a worse treatment outcome \[[@B5]\], and Binder et al. suggested that dysregulation of the HPA axis may even predict a nonresponse to antidepressant treatment particularly among males \[[@B3]\]. Both low CSF5-HIAA and DST nonsuppression contribute to a fourfold increased suicide risk in depressed subjects in a meta-analysis performed by Mann and Currier \[[@B18]\]. Some studies have reported no association between the DST test and individual susceptibility to suicide \[[@B27]\]. McGowan et al. observed epigenetic modification of the glucocorticoid receptor gene as a function of childhood abuse in the brains of suicide completers \[[@B20]\]. Thus, it is possible that HPA axis dysfunction is not linearly related to suicide risk \[[@B19]\]. Therefore, it would be interesting to study the polymorphisms of genes encoding receptors and transporters involved in the regulation of HPA axis function. Taking into account the limited number of genetic studies that have been published previously on the association between HPA axis genes and the history of suicide attempts, we aimed in the present study to investigate the possible association between *NR3C1*, *CRHR1*, and *AVPR1b* gene polymorphisms and suicidal behaviour in unipolar (UP) and bipolar (BP) patients.

2. Materials and Methods {#sec2}
========================

2.1. Patients {#sec2.1}
-------------

We included 597 patients (367 female, 230 male), aged 18--84 (mean = 47, SD = 14) who met DSM-IV criteria for bipolar disorder (391 BPI, 104 BPII) or recurrent depression (*n* = 102) and were living in the Wielkopolska region of Poland. The diagnosis was established using the Structured Clinical Interview for DSM-IV Axis I Disorders (SCID-I) \[[@B10]\]. Among patients with BP disorder, 197 people had a history of suicide attempt(s); among the UP patients, 28 people had a history of suicide attempt(s). The range of duration for disease in our group was 1--54 years (mean 15 years, SD = 11). Informed consent was obtained from each patient after the nature of the procedure had been fully explained to them.

2.2. Control Group {#sec2.2}
------------------

The control group consisted of 712 subjects. Control subjects were recruited from a group of healthy volunteers, blood donors and hospital staff, and students of the University of Medical Sciences in Poznan and the Clinical Neuropsychology Unit, Collegium Medicum Bydgoszcz. Only 40% of the control group were psychiatrically screened using the Polish version of the M.I.N.I. Plus scale to exclude individuals with any serious mental health problems. The mean age was 37.7, SD = 12.5. The control group was matched with age and sex. The study was approved by our local ethics committee.

2.3. Genotyping {#sec2.3}
---------------

DNA was extracted from using the salting out method \[[@B23]\]. SNP selection was carried out under the following criteria: functionality (in experimental functional studies), high frequency (MAF \> 0.05), indication as a tag SNP in HapMap, or previously reported associations with psychiatric disorders (both positive and negative findings). The SNPs chosen included both coding regions of known functionality and noncoding regions (introns, UTRs) that could affect gene regulation. The*NR3C1*, *CRHR1*, and *AVPR1b* polymorphisms were genotyped using TaqMan SNP Genotyping assays (Applied Biosystems) and TaqMan Genotyping Master Mix. The list of SNPs analysed and the ID numbers of the TaqMan assays were used according to previously described findings \[[@B15]\]. For each reaction plate, nontemplate controls (water) and genomic control DNA samples were included. To check for genotyping accuracy control TaqMan SNP genotyping assay was performed, 15% of randomly chosen samples from both groups, and identical genotypes were identified in all repeated samples. The clinical status of the subjects was not known during genotyping. The genotyping success rates were between 96.03% and 98.97%. The total number of genotyped patients differs on the different SNPs due to genotyping errors and therefore exclusions from further studies.

2.4. Statistical Analysis {#sec2.4}
-------------------------

Two-tailed Pearson\'s chi-squared (*χ* ^2^) test and Fisher\'s exact test were, respectively, used to test differences in the genotypic and allelic distribution between the groups of patients and the control subjects. Two-tailed power analysis was also performed. Calculations were performed using Statistica version 9.0. Odds ratios were calculated using 2 × 2 contingency tables by using Fisher\'s exact test in a demo version of GraphPad InStat 3 software. Linkage disequilibrium (LD) between the *CRHR1*, *AVPR1b*, and *NR3C1* polymorphisms was examined by pairwise comparisons of *r* ^2^ and *D*′ using Haploview version 4.1 \[[@B1]\]. Corrections for multiple testing were performed for multiple comparisons in the haplotype analysis and were completed for 10,000 permutations.

Higher-order gene-gene interactions among the tested SNPs were analysed using the nonparametric and genetic model-free multifactor dimensionality reduction (MDR) approach (v.2.0 beta 8.3). All interactions were tested using 10-fold cross-validation in an exhaustive search considering all possible SNP combinations. The model with the highest testing balance accuracy and cross-validation consistency of \>5 out of 10 was selected as the "best model." Statistical significance was determined using a 1000-fold permutation test (MDR permutation testing module, v.1.0 beta 2). The software is available online (<http://www.epistasis.org/>).

The power to detect an association for an odds ratio of 1.5 for our sample was about 80% for each SNP.

3. Results {#sec3}
==========

3.1. HWE Analysis {#sec3.1}
-----------------

The genotype distributions were in Hardy-Weinberg equilibrium, except the following polymorphisms: rs16940655 of *CRHR1*, rs10052957, and rs258813 of *NR3C1*, and rs28632197 of *AVPBR1* in the group of the patients and the control group. We did not include those polymorphisms into the further analysis.

3.2. Association Analysis {#sec3.2}
-------------------------

We did not observe any significant differences in the studied polymorphisms between the group of patients with a history of suicide attempts and the control subjects or in genotype distribution (results shown in Tables [1](#tab1){ref-type="table"}, [2](#tab2){ref-type="table"}, and [3](#tab3){ref-type="table"}, 0 = controls, 1 = suicidal patients) or allele frequencies (data not shown). Analysis stratified by gender also did not reveal any statistically significant differences between patients with suicide attempts and the control group (data not shown). We also compared the bipolar patients with the history of suicide attempts versus bipolar patients without suicide attempts in the past, but no significance was found between the two groups (data not shown).

3.3. Haplotype Analysis {#sec3.3}
-----------------------

Linkage disequilibrium analysis of the three analysed genes revealed strong linkage between the polymorphisms. For the *NR3C1* gene, we observed linkage for 5 out of 8 studied polymorphisms grouped in one haplotype block (*D*′ = 1.0, LOD = 39.11, *r* ^2^ = 0.162) ([Figure 1](#fig1){ref-type="fig"}).

However, none of the haplotypes were significantly more frequent in the group of patients with suicide attempts compared to the control group ([Table 4](#tab4){ref-type="table"}).

For the *CRHR1* gene, we observed linkage in 6 out of 7 polymorphisms grouped in two haplotype blocks: rs4076452, rs4792887, are rs110402 in one block (*D*′ = 1.0, LOD = 37.66, *r* ^2^ = 0.216) and rs173365, rs242950, and rs878886 in the other block (*D*′ = 1.0, LOD = 54.9, *r* ^2^ = 0.285) ([Figure 2](#fig2){ref-type="fig"}).

Our haplotype analysis did not reveal any significant differences in the haplotype frequencies of the two blocks between patients with suicide attempts and control subjects ([Table 5](#tab5){ref-type="table"}).

For the *AVPR1b*gene, we observed linkage disequilibrium for 3 out of 4 analysed polymorphisms grouped in one haplotype block (*D*′ = 0.98, LOD = 45.56, *r* ^2^ = 0.302) ([Figure 3](#fig3){ref-type="fig"}).

In our haplotype analysis, we observed an association between the GCA haplotype and suicide attempts; however, this association was not significant after correction for multiple testing (*P* value of 0.130 after 10,000 permutations) ([Table 6](#tab6){ref-type="table"}).

3.4. Gene × Gene Interaction Analysis {#sec3.4}
-------------------------------------

The results of our exhaustive MDR analysis evaluating combinations of all tested SNPs are summarised in [Table 7](#tab7){ref-type="table"}.

The best combination of possibly interactive polymorphisms in predicting suicidal attempts was observed in the 4-locus model. However, no significance was observed for this combination (the testing balanced accuracy for this 4-locus model was 90%, cross-validation consistency was 5/10 (50%), and an empiric *P* value of 0.589 is based on 1000-fold permutations). Similarly, other combinations of the analysed polymorphisms also did not reach statistical significance in predicting susceptibility to an increased risk of suicide attempts.

4. Discussion {#sec4}
=============

The results of our study suggested a possible association between the haplotype of the *AVPR1b*gene and suicide attempts, which did not reach significance after multiple testing correction. We did not find any interactions for genotypes or for the alleles of the studied polymorphisms in the group of suicidal patients. Also Dempster et al. suggested the involvement of the *AVPR1b* gene polymorphisms in the etiology of childhood onset mood disorders particularly in females \[[@B9]\]. Ben-Efraim et al. found association between the high Beck scale results in patients with suicide attempts and rs33990840 and a major 6-SNP haplotype of *AVPR1b* gene \[[@B2]\]. Previously, we reported the association between the rs28536160 polymorphism of the *AVPR1b* gene and rs1293651 of the *CRHR1*gene and bipolar patients with psychotic features \[[@B15]\]. In this study, we did not find association between polymorphisms of *CRHR1*gene and suicidal patients although Wasserman et al. identified a *CRHR1*SNP that showed an association in the suicide attempters exposed to low-medium stress and a relationship between neurotic personality traits and suicidality. The genetic variation in the *TBX19* gene (a regulator of the HPA axis) was observed by Wasserman et al. \[[@B30], [@B31]\]. In suicidal males, they found an association between the T and A alleles of SNPs rs4792287 and rs110402 and the T allele of rs12936511 of the *CRHR1* gene. Polymorphisms in the *CRHR1* gene have also been associated with depression and the treatment efficiency of depression \[[@B4]--[@B24]\]. Papiol et al. showed associations of the A allele of the *CRHR1* rs110402 SNP with hte age of onset and with seasonal pattern of major depression \[[@B24]\]. Bradley et al. reported that the T and G alleles of the rs4792887 and rs110402 *CRHR1* SNPs were linked with depression \[[@B4]\]. In the study performed by De Luca et al. an association between haplotype variation at the CRHR2 locus and suicidal behaviour was observed \[[@B7]\]. Interestingly, they also found interactions between polymorphisms of *CRHR1*gene in suicidal schizophrenic patients \[[@B8]\]. We did not find an association between the polymorphisms of the *NR3C1*, *CRHR1,* and *AVPBR1* genes and the whole group of affective disorder patients (data not published). However, in the study performed by Szczepankiewicz et al. \[[@B29]\], an association between *NR3C1* polymorphisms and depression was found.

The main limitations of our study that might have yielded false-positive or- negative results include the following: the limited sample size of the patient group (*n* = 225), the fact that only 40% of the control group had been screened for psychiatric disorders, and the lack of Hardy-Weinberg equilibrium for the four analysed SNPs. However, taking into consideration the lifetime prevalence of psychiatric disorders and the power of the studied polymorphisms (\>80%), it seems unlikely that these factors affected our results.

5. Conclusions {#sec5}
==============

We report here a comprehensive analysis of HPA axis genes and a lack of association of genetic variation with the risk of suicide attempts in affective disorder patients. Nonetheless, the inconsistencies with the previously published associations indicate the importance of further investigation of those polymorphisms with respect to the risk of suicide attempts.
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###### 

Polymorphisms in *GR* (*NR3C1*) gene (genotypes).

  rs41423247   CC    CG      GG    *P*                   
  ------------ ----- ------- ----- ------- ----- ------- ------
  0            65    13.03   239   47.9    195   39.8    0.55
  1            27    13.5    87    43.5    86    43       
                                                         
  rs6195       CC    CT      TT    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            450   88.93   56    11.07   0     0       0.28
  1            177   88.5    22    11.0    1     0.5      
                                                         
  rs6198       CC    CT      TT    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            14    2.8     116   23.2    370   74      0.33
  1            3     1.53    54    27.55   139   70.92    
                                                         
  rs6191       AA    AC      CC    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            136   27.15   244   48.7    121   24.15   0.72
  1            57    29.38   88    45.36   49    25.26    
                                                         
  rs6196       AA    AG      GG    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            366   72.05   129   25.39   13    2.56    0.2
  1            146   73      53    26.5    1     0.5      
                                                         
  rs33388      AA    AT      TT    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            138   27.27   245   48.42   123   24.31   0.84
  1            58    29.15   92    46.23   49    24.62    

0: control. 1: suicidal patients.

###### 

Polymorphisms in *AVPR1b* gene (genotypes).

  rs28536160   CC    CT      TT    *P*                   
  ------------ ----- ------- ----- ------- ----- ------- ------
  0            2     0.4     73    14.48   429   85.12    
  1            0     0       22    11      178   89      0.31
                                                         
  rs28373064   AA    AG      GG    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            349   68.84   139   27.42   19    3.75     
  1            133   66.5    60    30      7     3.5     0.78
                                                         
  rs35369693   CC    CG      GG    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            1     0.2     51    10.39   439   89.41   0.09
  1            0     0       31    16.15   161   83.85    

0: control. 1: suicidal patients.

###### 

Polymorphisms of *CRHR1* gene (genotypes).

  rs4076452    CC    CG      GG    *P*                   
  ------------ ----- ------- ----- ------- ----- ------- ------
  0            11    2.54    142   32.79   280   64.67   0.48
  1            5     3.09    45    27.78   112   69.14    
                                                         
  rs12936511   CC    CT      TT    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            394   91.8    34    7.93    1     0.23     
  1            149   91.98   12    7.41    1     0.62    0.75
                                                         
  rs4792887    CC    CT      TT    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            332   77.2    94    21.86   4     0.93     
  1            130   79.75   32    19.63   1     0.61    0.77
                                                         
  rs242950     CC    CT      TT    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            325   75.4    99    22.97   7     1.62    0.81
  1            126   77.78   34    20.99   2     1.23     
                                                         
  rs878886     CC    CG      GG    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            304   70.2    118   27.25   11    2.5     0.5
  1            106   65.4    51    31.48   5     3.09     
                                                         
  rs173365     AA    AG      GG    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            78    18.01   206   47.58   149   34.41   0.9
  1            28    17.18   77    47.24   58    35.58    
                                                         
  rs110402     AA    AG      GG    *P*                   
  *n*          \%    *n*     \%    *n*     \%            
                                                         
  0            98    22.9    216   50.47   114   26.64    
  1            39    24.07   87    53.7    36    22.22   0.5

0: control. 1: suicidal patients.

###### 

Comparison of haplotype frequencies for the analysed *NR3C1* polymorphisms between patients with suicide attempts and the control group.

  Haplotype   Haplotype frequency   Case : control ratio   *χ* ^2^   *P*
  ----------- --------------------- ---------------------- --------- -------
  Block 1                                                            
  TCAGT       0.478                 0.475 : 0.479          0.015     0.901
  TAAGA       0.222                 0.218 : 0.224          0.072     0.788
  CAAAA       0.150                 0.170 : 0.142          1.711     0.190
  TAGAA       0.144                 0.135 : 0.147          0.332     0.564

###### 

Comparison of haplotype frequencies for the analysed *CRHR1*polymorphisms between patients with suicide attempts and the control group.

  Haplotype   Haplotype frequency   Case : control ratio   *χ* ^2^   *P*
  ----------- --------------------- ---------------------- --------- -------
  Block 1                                                            
  GCA         0.489                 0.510 : 0.481          0.755     0.385
  GCG         0.323                 0.321 : 0.323          0.0050    0.943
  CTG         0.110                 0.104 : 0.112          0.166     0.683
  CCG         0.074                 0.065 : 0.077          0.487     0.485
                                                                     
  Block 2                                                            
  GCC         0.584                 0.592 : 0.581          0.118     0.731
  ACG         0.169                 0.187 : 0.162          1.061     0.303
  ATC         0.127                 0.118 : 0.130          0.312     0.576
  ACC         0.120                 0.103 : 0.127          1.29      0.256

###### 

Comparison of haplotype frequencies for the analysed *AVPR1b* polymorphisms between patients with suicide attempts and the control group.

  Haplotype   Haplotype frequency   Case : control ratio   *χ* ^2^   *P*
  ----------- --------------------- ---------------------- --------- -------------
  Block 1                                                            
  AGG         0.823                 0.814 : 0.826          0.291     0.589
  GGG         0.076                 0.068 : 0.079          0.547     0.459
  GCA         0.060                 0.081 : 0.052          4.087     **0.043**\*
  GGA         0.041                 0.037 : 0.042          0.162     0.687

\*Not significant after correction for multiple test using 10.000 permutations (*P* = 0.130).

###### 

Multilocus interaction model for the risk of suicide attempts with the *NR3C1. AVPR1b* and *CRHR1*genes by the MDR method.

  Model     Loci combination                                                                   Testing balanced accuracy (%)   Cross-validation consistency (%)   *P* value
  --------- ---------------------------------------------------------------------------------- ------------------------------- ---------------------------------- -----------
  2-locus   Rs258813 of *NR3C1* and rs110402 of *CRHR1*                                        47                              30                                 0.989
  3-locus   Rs41423247 and rs258813 of *NR3C1* and rs110402 of *CRHR1*                         52                              50                                 0.760
  4-locus   Rs41423247 and rs258813 of *NR3C1*. rs28373064 of AVPR1b and rs110402 of *CRHR1*   50                              90                                 0.589
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